2024

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life
Braun B, Fischbach F, Richter J, Pfeffer L, Fay H, Reinhardt S, Friese M, Stellmann J, Kröger N, Heesen C, Häußler V
MULT SCLER RELAT DIS. 2024;82:105414.

Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies
Eisenhut K, Faber J, Engels D, Gerhards R, Lewerenz J, Doppler K, Sommer C, Markewitz R, Falk K, Rössling R, Pruess H, Finke C, Wickel J, Geis C, Ratuszny D, Pfeffer L, Bittner S, Piepgras J, Kraft A, Klausewitz J, Nuscher B, Kümpfel T, Thaler F
NEUROL-NEUROIMMUNOL. 2024;11(1):.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024;5(6):550-558.e2.

Current state and perspectives of CAR T cell therapy in central nervous system diseases
Pfeffer L, Fischbach F, Heesen C, Friese M
BRAIN. 2024 [Epub ahead of print].

Sex- and species-specific contribution of CD99 to T cell costimulation during multiple sclerosis
Winschel I, Willing A, Engler J, Walkenhorst M, Meurs N, Binkle-Ladisch L, Woo M, Pfeffer L, Sonner J, Borgmeyer U, Hagen S, Grünhagel B, Claussen J, Altfeld M, Friese M
BIOL SEX DIFFER. 2024;15(1):41.

2020

Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
Gerhards R, Pfeffer L, Lorenz J, Starost L, Nowack L, Thaler F, Schlüter M, Rübsamen H, Macrini C, Winklmeier S, Mader S, Bronge M, Grönlund H, Feederle R, Hsia H, Lichtenthaler S, Merl-Pham J, Hauck S, Kuhlmann T, Bauer I, Beltran E, Gerdes L, Mezydlo A, Bar-Or A, Banwell B, Khademi M, Olsson T, Hohlfeld R, Lassmann H, Kümpfel T, Kawakami N, Meinl E
ACTA NEUROPATHOL COM. 2020;8(1):207.

Letzte Aktualisierung aus dem FIS: 01.12.2024 - 23:34 Uhr